High-Risk Melanoma
Merck and Moderna Commence Phase III Study of V940 with KEYTRUDA for High-Risk Melanoma
SG Tylor
Source – Merck Moderna and Merck announced the commencement of the pivotal Phase III randomized V940-001 clinical trial. This trial ...